

Prescribing other hydrocodone/acetaminophen products for >10 days¹ may

OVERLOAD THE LIVER



XODOL - pain relief that reduces overload

Only XODOL® combines the efficacy of hydrocodone with the lowest dose of APAP—for effective pain relief while reducing the potential for hepatotoxicity^{2,3}



Acetaminophen content in commonly prescribed combinations at highest indicated dose*

APAP strength	300 mg	500 mg	650 mg	660 mg	750 mg
Brand	XODOL® 5/300 XODOL® 7.5/300 XODOL® 10/300	Lorcet® HD† Lortab®† Vicodin®†	Lorcet® Lorcet® Plus	Vicodin® HP	Vicodin® ES

*Based on the package insert for each product.


†Lorcet, Lortab, and Vicodin are registered trademarks of their respective owners.

Daily adult APAP consumption guidelines have been established to minimize hepatotoxicity

- 4000 mg/day for <10 days
- 2600 mg/day for >10 days

Start and stay with XODOL® for effective pain relief that complies with APAP guidelines^{1,3}

XODOL® is appropriate for use >10 days even when taken at the highest recommended dosage



Extend therapy >10 days without changing brand or dosage strength

Safety Profile

- Safety and effectiveness in pediatric patients have not been established.
- As with all Schedule III hydrocodone products, patients known to be hypersensitive to opioids may exhibit cross sensitivity to hydrocodone. At high doses or in sensitive patients, hydrocodone may produce dose-related respiratory depression.
- The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions. Patients should be cautioned that hydrocodone, like all narcotics, may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
- Alcohol and other CNS depressants may produce an additive CNS depression when taken with this
 combination product and should be avoided. Hydrocodone may be habit-forming. Patients should
 take this drug only for as long as and in the amounts it is prescribed.



Please consult accompanying complete Prescribing Information for XODOL® 5/300, 7.5/300, and 10/300.

XODOL® relieves the pain while reducing the risk

Efficacy of hydrocodone...Lowest APAP dose

• XODOL® is the only family of hydrocodone/acetaminophen products that contains 300 mg APAP—the lowest effective fixed combination available²

 XODOL® provides effective pain relief and complies with APAP consumption guidelines when used for >10 days^{1,3}

XODOL® 5/300
#60 (sixty)
1-2 tablets PO
q 4-6 hrs prn
not to exceed
8 tablets/day

XODOL® 7.5/300
#60 (sixty)
1 tablet PO
q 4-6 hrs prn
not to exceed
6 tablets/day

XODOL® 10/300
#60 (sixty)
1 tablet PO
q 4-6 hrs prn
not to exceed
6 tablets/day

Safety Profile

- The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting.
- In acetaminophen overdosage, dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma, and thrombocytopenia may also occur.
- As with any narcotic analgesia agent, XODOL® tablets should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture. The usual precautions should be observed, and the possibility of respiratory depression should be kept in mind.



(hydrocodone* bitartrate/acetaminophen) tablets *Warning: May be habit-forming.

Relieves the pain. Reduces the risk.

Please consult accompanying complete Prescribing Information for XODOL® 5/300, 7.5/300, and 10/300.

References: 1. Shands at the University of Florida. Drugs and Therapy Bulletin. 2002;16(5). Available at: http://shands.org/professionals/druglnfo/bulletins/0502.pdf. Accessed June 14, 2007. 2. Wolters Kluwer Health. Facts & Comparisons 4.0. St. Louis, MO. Available at: http://www.factsandcomparisons.com. Accessed November 16, 2006. 3. XODOL® [package insert]. San Diego, CA: Victory Pharma Inc.; 2006.

www.victorypharma.com

© 2007 Victory Pharma, Inc.



XOD017A0507